Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1335-1341

  Gao, Liuwei ^a,b   Liu, Jun ^a,b   Zhang, Bin ^a,b   Zhang, Hua ^a,b   Wang, Daowei ^a,b   Zhang, Tiemei ^a,b   Liu, Yang ^a,b   Wang, Changli ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

E cadherin; EMT; Lung adenocarcinoma; MUC4; Vimentin; catenin

Indexed keywords

BETA CATENIN; COMPLEMENTARY RNA; MUCIN 4; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; CELL STRUCTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR XENOGRAFT; UPREGULATION;

ADENOCARCINOMA; ANIMALS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE; MUCIN-4; NEOPLASM METASTASIS; PROGNOSIS; SIGNAL TRANSDUCTION; VIMENTIN;

EID: 84899092745     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1178-0     Document Type: Article

References (38)

1. Nakamura N et al. Identification of tumour markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 2006;25(30):4245-55. (Pubitemid 44079459)
2. Feldser DM et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 2010;468(7323):572-5.
3. Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 2007;185(1-3):7-19. (Pubitemid 46956838)
4. Kyprianou N. ASK-ing EMT not to spread cancer. Proc Natl Acad Sci U S A. 2010;107(7):2731-2.
5. Shintani Yet al. Epithelial tomesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1794-804. discussion 1804.
6. Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to- mesenchymal transition in lung carcinogenesis. Respirology. 2012;17(7):1048-59.
7. Kim AN et al. Fyn mediates transforming growth factor-beta1-induced downregulation of E-cadherin in human A549 lung cancer cells. Biochem Biophys Res Commun. 2011;407(1):181-4.
8. Puisieux A. Role of epithelial-mesenchymal transition in tumour progression. Bull Acad Natl Med. 2009;193(9):2017-32. discussion 2032-4.
9. Lee JM et al. The epithelial-mesenchymal transition: new insights in signalling, development, and disease. J Cell Biol. 2006;172(7):973-81.
10. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420-8.
11. Nozawa N et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract. 2006;202(9):639-50.
12. Kwon KY et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumour histology and patient survival. Arch Pathol Lab Med. 2007;131(4):593-8. (Pubitemid 46564433)
13. Carraway KL et al. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2001;6(3):323-37.
14. Singh AP et al. Inhibition of MUC4 expression suppresses pancreatic tumour cell growth and metastasis. Cancer Res. 2004;64(2):622-30. (Pubitemid 38120902)
15. Ogata S et al. Mucin gene expression in colonic tissues and cell lines. Cancer Res. 1992;52(21):5971-8.
16. Lopez-Ferrer A et al. MUC4 expression is increased in dysplastic cervical disorders. Hum Pathol. 2001;32(11):1197-202.
17. Shibahara H et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004;39(1):220-9. (Pubitemid 38461485)
18. Majhi PD et al. Pathobiological implications of MUC4 in non-smallcell lung cancer. J Thorac Oncol. 2013;8(4):398-407.
19. Giuntoli RN et al.Mucin gene expression in ovarian cancers. Cancer Res. 1998;58(23):5546-50.
20. Weed DT et al. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes. Laryngoscope. 2004;114(8 Pt 2 Suppl 101):1-32. (Pubitemid 39045495)
21. Weed DT et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck. 2004;26(4):353-64. (Pubitemid 38436675)
22. Braun J et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29(29):4237-44.
23. Vuoriluoto K et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436-48.
24. Kupferman ME et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene. 2010;29(14):2047-59.
25. Hiscox S et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118(2):290-301. (Pubitemid 41779067)
26. Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem celllike characters. BMC Cancer. 2011;11:49.
27. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442-54.
28. Wang C et al. The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PLoS One. 2012;7(9):e38046.
29. Horn G et al. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumour cells induced by truncated MUC1. Exp Cell Res. 2009;315(8):1490-504.
30. Ponnusamy MP et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010;29(42):5741-54.
31. Conacci-Sorrell M et al. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signalling, Slug, and MAPK. J Cell Biol. 2003;163(4):847-57. (Pubitemid 37517891)
32. Asnaghi L et al. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene. 2010;29(19):2760-71.
33. Lee W et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010;465(7297):473-7.
34. Hata Aet al. Erlotinib after Gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011;74(2):268-73.
35. Longo F et al. Long-term survival in a smoking Caucasian male patient treated with Gefitinib for spinal cord compression secondary to lung cancer. Onkologie. 2011;34(6):326-8.
36. Rich AL et al. How do patient and hospital features influence outcomes in small-cell lung cancer in England? Br J Cancer. 2011;105(6):746-52.
37. Weng JH et al. Pituitary FDG uptake in a patient of lung cancer with bilateral adrenal metastases causing adrenal cortical insufficiency. Clin Nucl Med. 2011;36(8):731-2.
38. Tsutsumida H et al.MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55(2):195-203. (Pubitemid 46074231)